Impact of anti-cancer drugs on antibody-based complement-mediated tumor cell killing
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
Heidelberg, Universität Heidelberg, Dissertation, 2022
- Schlagwort
-
Cancer
Impact
Drugs
- Ereignis
-
Veröffentlichung
- (wo)
-
Heidelberg
- (wer)
-
Universitätsbibliothek Heidelberg
- (wann)
-
2022
- Beteiligte Personen und Organisationen
- DOI
-
10.11588/heidok.00031890
- URN
-
urn:nbn:de:bsz:16-heidok-318907
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nasrh, Mohamed Hassan Atia Hassan
- Kirschfink, Michael
- Universitätsbibliothek Heidelberg
Entstanden
- 2022
Ähnliche Objekte (12)
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Synthetic cannabinoids - identification, quantification and antibody-based detection
Advances in antibody-based HIV-1 vaccines development
Single-domain antibody-based protein degrader for synucleinopathies
Advances in antibody-based hiv-1 vaccines development
Antibody‐Based CAR T Cells Produced by Lentiviral Transduction
Antibody-based SAW sensor for the detection of explosives
Antibody‐based proteomics and biomarker research—Current status and limitations
Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo
Hapten synthesis for the antibody-based detection of diclofenac in water samples
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Synthetic cannabinoids - identification, quantification and antibody-based detection
Advances in antibody-based HIV-1 vaccines development
Single-domain antibody-based protein degrader for synucleinopathies
Advances in antibody-based hiv-1 vaccines development
Antibody‐Based CAR T Cells Produced by Lentiviral Transduction
Antibody-based SAW sensor for the detection of explosives
Antibody‐based proteomics and biomarker research—Current status and limitations
Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo
Hapten synthesis for the antibody-based detection of diclofenac in water samples
Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics
Synthetic cannabinoids - identification, quantification and antibody-based detection
Advances in antibody-based HIV-1 vaccines development
Single-domain antibody-based protein degrader for synucleinopathies
Advances in antibody-based hiv-1 vaccines development
Antibody‐Based CAR T Cells Produced by Lentiviral Transduction
Antibody-based SAW sensor for the detection of explosives
Antibody‐based proteomics and biomarker research—Current status and limitations
Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis
New CEACAM-targeting 2A3 single-domain antibody-based chimeric antigen receptor T-cells produce anticancer effects in vitro and in vivo